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Abstract 
Although knowledge of human renal cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT) 
enzymes and their role in xenobiotic and endobiotic metabolism is limited compared with hepatic 
drug and chemical metabolism, accumulating evidence indicates that human kidney has significant 
metabolic capacity. Of the drug metabolizing P450s in families 1 to 3, there is definitive evidence for 
only CYP 2B6 and 3A5 expression in human kidney. CYP 1A1, 1A2, 1B1, 2A6, 2C19, 2D6 and 2E1 are 
not expressed in human kidney, while data for CYP 2C8, 2C9 and 3A4 expression are equivocal. It is 
further known that several P450 enzymes involved in the metabolism of arachidonic acid and 
eicosanoids are expressed in human kidney, CYP 4A11, 4F2, 4F8, 4F11 and 4F12. With the current 
limited evidence of drug substrates for human renal P450s drug–endobiotic interactions arising from 
inhibition of renal P450s, particularly effects on arachidonic acid metabolism, appear unlikely. With 
respect to the UGTs, 1A5, 1A6, 1A7, 1A9, 2B4, 2B7 and 2B17 are expressed in human kidney, 
whereas UGT 1A1, 1A3, 1A4, 1A8, 1A10, 2B10, 2B11 and 2B15 are not. The most abundantly 
expressed renal UGTs are 1A9 and 2B7, which play a significant role in the glucuronidation of drugs, 
arachidonic acid, prostaglandins, leukotrienes and P450 derived arachidonic acid metabolites. 
Modulation by drug substrates (e.g. NSAIDs) of the intrarenal activity of UGT1A9 and UGT2B7 has 
the potential to perturb the metabolism of renal mediators including aldosterone, prostaglandins 
and 20-hydroxyeicosatetraenoic acid, thus disrupting renal homeostasis. 
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Introduction 
‘The kidneys are of a glandular nature, but redder in colour, like the liver, … Their cavities are small 
and like sieves, for the percolation of the urine. …’ Aretaeus, the Cappadocian, 1st century BC [1]. 
The kidneys carry out a number of highly integrated functions that include maintenance of body 
fluid (composition and volume), electrolytes and acid-base balance, regulation of blood pressure via 
orchestrated changes in sodium balance and the synthesis and secretion of renin, along with the 
production of vasoactive eicosanoids, the synthesis of erythropoietin and 1,25-dihydroxyvitamin D3 
and the excretion of polar chemicals and metabolites, the latter arising from both xenobiotic and 
intermediary metabolism. 
Despite evidence of significant endogenous synthetic and catabolic capacity, in terms of drug 
metabolism the general assumption has been (is) that the metabolic clearance of drugs is 
determined principally, if not exclusively, by the liver while the kidneys contribute minimally to the 
metabolic clearance of drugs. The contribution of the kidney to drug metabolic clearance is generally 
predicted to be less than that of liver given the lower organ weight and microsome yield of the 
kidneys [2]. However, in vitro–in vivo extrapolation of kinetic data is not possible in the absence of a 
valid model of renal metabolic clearance. Nevertheless, there is now a wealth of in vitro and in vivo 
data clearly demonstrating that human kidney has significant drug metabolizing capacity that in 
some instances surpasses that of liver [3]. For example, the intrinsic clearance (CLint) of the 
glucuronidated substrates mycophenolic acid and 4-methylumbelliferone by human kidney 
microsomes are comparable with those of human liver microsomes [4, 5]. Additionally, the maximal 
rate of propofol glucuronidation by human kidney microsomes is 3–4 times greater than that of 
human liver microsomes [6, 7]. Not surprisingly, total systemic clearance of propofol in humans has 
been reported to exceed hepatic blood flow [8]. Further data from in vivo studies in humans 
demonstrated extrahepatic elimination of propofol in liver transplant patients during the anhepatic 
stage [9, 10] and identified the kidneys as contributing almost one-third of total systemic clearance 
[11]. Similar to propofol the systemic clearance of morphine in humans has been reported to exceed 
hepatic clearance by 38%. The authors concluded that in the absence of evidence of gut wall 
metabolism it could be reasonably concluded that the site of extrahepatic metabolism in humans 
was the kidney [12]. 
Clearly the kidneys, in addition to their traditional role of excreting a myriad of xenobiotics, 
xenobiotic metabolites and metabolites of intermediary metabolism, possess significant xenobiotic 
metabolizing capacity. The human kidneys express an array of enzymes variably involved in 
xenobiotic metabolism (e.g. N-acetyltransferases, sulfotransferases and glutathione transferases) 
[3]. However, this review will focus on cytochrome P450 (CYP) and UDP-glucuronosyltransferases 
(UGT), enzymes that are integral to systemic and intrarenal clearance of both endo- and xeno-
biotics, including drugs. 
Human cytochrome P450 
Human cytochrome P450 exists as a superfamily of haem containing enzymes that catalyze the 
oxidative metabolism of a myriad of compounds. Indeed, P450 catalyzed pathways serve as a key 
clearance mechanism, as well as terminating the actions of a range of endogenous and exogenous 
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compounds including drugs from all therapeutic classes (Table 1), steroid hormones, eicosanoids, 
cholesterol, vitamins, fatty acids and bile acids [13]. 
There are 60 known human P450 genes, which are classified into 18 gene families and 43 subfamilies 
on the basis of sequence identity [14]. Enzymes of the CYP1, CYP2 and CYP3 families are primarily 
responsible for the metabolism of drugs and other non-drug xenobiotics [13], while enzymes from 
the remaining P450 families play key roles in the synthesis and metabolism of endogenous 
compounds. In this regard, individual P450 enzymes exhibit distinct, but overlapping, patterns of 
substrate and inhibitor selectivity [15, 16]. The tertiary structures of several human P450 enzymes, 
including CYP1A2, 2A6, 2C8, 2C9, 2D6 and 3A4, have been elucidated by X-ray crystallography in 
recent years and the amino acids that form the substrate binding pocket identified [17-20]. 
 
Substrates of human renal P450s 
In terms of the human kidney knowledge of P450s and the role they play in both endo- and xeno-
biotic metabolism is surprisingly lacking. In some instances the data are conflicting and in others, 
although purported to pertain to human kidney, the primary data often relates to rat, rabbit and 
mouse kidney. In 1972 the first study characterizing P450 activity using human kidney cortical 
microsomes reported not only metabolism of aminopyrine via demethylation but a comparable rate 
of ω- and ω-1 hydroxylation of lauric acid [21]. P450 mediated metabolism of arachidonic acid (AA, 
C20:4) using rabbit kidney cortical microsomes was unequivocally demonstrated in 1981 with 
identification of 19- and 20-hydroxyeicosatetraenoic acids (19-, 20-HETE) [22]. Subsequently, Karara 
et al. reported that homogenates of post-mortem human kidney cortex contained 8,9 
epoxyeicosatrienoic acid (8,9-EET), 11,12-EET and 14,15-EET, the latter constituting 44% of the total 
concentration of EETs. The authors concluded that EETs were ‘endogenous constituents of human 
kidney cortex generated in vivo by the tissue arachidonic acid epoxygenase’ and that in view of the 
biological activity of EETs P450s controlled renal function [23]. Using human kidney cortical 
microsomes, again prepared from post-mortem renal tissue, the formation of 19-HETE, 20-HETE and 
11,12-EET was reported by Schwartzman et al. [24]. 
Thereafter, the relevance of and interest in renal xenobiotic metabolism and AA metabolism 
languished while work continued to focus on hepatic P450s and the cyclooxygenase (COX) and 
lipoxygenase (LOX) enzymes involved in the metabolism of AA. The focus on AA metabolism changed 
in the mid-1990s following recognition of the physiological and biochemical importance of AA 
derived metabolites in the modulation of cardiac, pulmonary, renal and vascular function, and 
inflammation and angiogenesis [25, 26]. The AA cascade includes three main pathways; 
(i) metabolism by COX generates the unstable cyclic endoperoxide prostaglandin H2 (PGH2), an 
obligatory intermediate in the formation of PGE2, PGF2α, PGD2, PGI2 (prostacyclin) and 
thromboxane (TXA2), (ii) the LOX pathway generates several allylic hydroperoxides containing a cis-
trans conjugated diene functionality such as 5-hydroperoxyeicosatetraenoic acid (5-HPETE), which is 
the precursor to the formation of the leukotrienes and (iii) the P450 pathway. The latter involves 
metabolism of AA by a number of different types of reactions: 
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    bis-allylic oxidation (LOX-like reaction) generating six regioisomeric HETEs, 5-, 8-, 9-, 11-, 12- and 
15-HETE, 
    hydroxylation (ω/ω-1 hydroxylase) at or near the terminal carbon to form 16-HETE (ω-4), 17-HETE 
(ω-3), 18-HETE (ω-2), 19-HETE (ω-1) and 20-HETE (ω) and 
    olefin epoxidation (AA epoxygenase) generating four regioisomeric EETs, 5,6-, 8,9-, 11,12- and 
14,15-EET. 
P450s, both hepatic and renal, that variously play a key role in the metabolism of xenobiotics and 
fatty acids include enzymes of the CYP1A, 2B, 2C, 2D, 2E, 2J, 3A, 4A, 4B and 4F sub-families [26]. 
However, the number of studies that have specifically investigated P450 mediated xenobiotic and 
fatty acid metabolism using human kidney are limited and, moreover, it is apparent that 
extrapolation from animals to humans is problematic. Of the studies that have used human kidney, 
and acknowledging issues such as antibody specificity and sensitivity of the techniques used (e.g. 
Northern blots, immunoblotting, activity assays), it has been reported that CYP 2B6, 3A5, 4A11, 4F2, 
4F8, 4F11 and 4F12 are expressed in human kidney [27-30]. While expression of CYP 1A1, 1A2, 1B1, 
2A6, 2C19, 2D6, and 2E1 has not been reported in human kidney (see later sections), the data 
regarding CYP 2C8, 2C9, 3A4 and 2J2 are equivocal. 
A cDNA coding for CYP2C8 was isolated from a human kidney library and the expressed protein 
catalyzed formation of 11,12- and 14,15-EET (Table 2). However, use of a sequence specific 
oligonucleotide for CYP2C8 in Northern blot analyses failed to detect mRNA transcripts encoding 
CYP2C8 [31]. Subsequent studies either combining Northern blot analysis and immunoblotting [32] 
or using immunoblotting alone did not report the presence of CYP2C8 mRNA or expression of 
CYP2C8 protein in human kidney [30]. In contrast, using immunohistochemistry and a semi-
quantitative scoring of staining intensity, CYP2C8 protein expression was reported in normal human 
kidney tissues in ∼50% of the individual tissues studied [33]. Definitive determination of either the 
presence or absence of CYP2C8 in human kidney remains unresolved. 
In addition to a role in drug metabolism (e.g. paclitaxel 6α-hydroxylation) CYP2C8 is the primary 
hepatic enzyme responsible for the formation of 11,12- and 14,15-EET and is thought to contribute 
substantially to the systemic concentration of circulating EETs [32]. Genetic polymorphism of CYP2C8 
was identified in 2001 and the polymorphic alleles CYP2C8*2 and CYP2C8*3 were associated with 
markedly deficient metabolism of both paclitaxel and AA. It was concluded that not only were there 
clinical ramifications in terms of paclitaxel elimination but also with regard to the diminished 
production of physiologically relevant EETs that function as autocrine and paracrine mediators [34]. 
Similarly the data regarding expression of CYP2C9 [27, 30], CYP3A4 [27, 30, 35-37] and CYP2J2 [33, 
38] in human kidney are equivocal, although the weight of evidence suggests that CYP2C9 is not 
present. The data regarding expression of CYP3A4 in human kidney are highly variable. Using 
Western blotting, Baker et al. [27] reported that CYP3A4 protein was not present in nine samples of 
kidney cortical microsomes. Again using immunoblotting CYP3A3/4 protein expression was reported 
in one out of seven [36] and six out of nine kidneys tested [37]. Further, CYP3A4 mRNA was reported 
in only 11 of 27 human kidney samples [35]. The significance of absent/variable CYP3A4 expression 
in human kidneys remains to be fully elucidated. 
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Conflicting data have been reported for CYP2J2 in that barely detectable levels of total RNA were 
reported for human kidney [38]. In contrast, an immunohistochemical study identified CYP2J2 
protein expression in ∼50% of the human kidney tissue samples analyzed [33]. Further, in those 
tissues where P450 catalyzes epoxygenation a relationship between the formation of EETs and 
CYP2J2 content was not established [30]. 
It is apparent that a number of P450s that are expressed in liver variously metabolize xenobiotics 
(with the exception of CYP2J2) and fatty acids, including the conversion of linoleic acid to 11-
hydroxyoctadecadienoic acid (11-HODE) (Table 2) [39-41]. As has been previously reported in the 
literature, the liver appears to be the organ that predominately metabolizes AA to EETs [42]. This 
tenet is supported by evidence, albeit limited, of lack of expression of the relevant renal human 
P450s that metabolize AA to EETs. Thus, renal drug–endobiotic interactions involving CYP 1A2, 2C8, 
2C9, 2C19, 2E1, 2J2 and 3A4 are unlikely. The P450s that are reported to be expressed in human 
kidney include CYP 2B6, 3A5, 4A11, 4F2, 4F8, 4F11 and 4F12 (Table 3) [43-54]. 
CYP2B6 
CYP2B6 is a highly polymorphic enzyme that is known to contribute (3–12%) to the metabolism of 
therapeutic drugs (Table 1) [41]. In addition to the metabolism of drugs that include 
chemotherapeutics, anti-retrovirals, anti-inflammatories, anaesthetics and benzodiazepines [45], 
CYP2B6 also metabolizes environmental chemicals including insecticides, herbicides and a small 
number of industrial chemicals [46]. In terms of endogenous metabolism, CYP2B6 catalyzes 
formation of the quinols of estrone and 17β-estradiol [43], 4-hydroxy-, 4-oxo-, and 18-hydroxy-
retinoic acid, which are the principal metabolites of all-trans-retinoic acid [44], and to a limited 
extent the 6β-hydroxy metabolites of testosterone and 17α-methyltestosterone [55]. Both Northern 
blot analysis and immunoblotting confirmed the presence of CYP2B6 mRNA and protein, 
respectively, in human kidney [56]. Further, using 7-ethoxy-4-fluoro-coumarin as a probe for CYP2B6 
activity, Aleksa et al. reported 13-fold variability in activity in a panel of microsomes from 10 human 
kidneys [37]. 
CYP3A5 
Using microsomes from 29 human kidneys the metabolism of midazolam to 1'-hydroxymidazolam 
was used to assess the activity of renal CYP3A4/3A5. Activity varied 134-fold and high activity was 
related to higher expression of CYP3A5 [35]. CYP3A4 protein was undetectable in the majority of the 
kidneys. CYP3A5 is expressed to a 1.5-fold greater extent in the cortex than in the medulla of human 
kidney [36] and immunostaining of CYP3A5 indicates localization in the apical membrane of the 
proximal and distal tubules [57]. 
Cortisol is metabolized by CYP3A5 to 6β-hydroxycortisol which, in a variety of animal models, has 
been shown to cause salt retention and to enhance sodium transport suggesting a possible link with 
salt sensitive hypertension. A single nucleotide polymorphism (A6986G) in the CYP3A5 gene has 
been shown to distinguish either the (*1) ‘expressor’ allele or the (*3) ‘reduced expressor’ allele, 
which largely predicts CYP3A5 content in liver [58]. A subsequent comparative in vitro–in vivo study 
investigated a link between CYP3A5 genotype, CYP3A5 expression and blood pressure using tissue 
from 21 kidney donors and 25 healthy African-American adults. Renal microsomes from individuals 
carrying the *1/*3 alleles had >8-fold higher CYP3A5 content and 18-fold higher formation of 1'-
6 
 
hydroxymidazolam than microsomes from individuals identified as homozygous for the CYP3A5*3 
alleles. Subsequent genotyping of the 25 African-American individuals indicated that the mean 
systolic blood pressure of individuals homozygous for CYP3A5 *1 was raised by 19.3 mmHg in 
comparison with individuals homozygous for CYP3A5 *3. This led the authors to speculate an 
association between the CYP3A5 *1 genotype and salt sensitive hypertension in African-Americans 
[59]. However, the relationship between CYP3A5 genotype and cortisol metabolism by human 
kidney has yet to be established. 
The three primary metabolites of the calcineurin inhibitor cyclosporin, AM1, AM9 and AM4N are less 
nephrotoxic than the parent compound and hence metabolism is considered a detoxification 
process. Analogous to recombinant CYP3A5, human kidney microsomes produce only the AM9 
metabolite and the extent of formation shows a significant association with CYP3A5 content and 
presence of the CYP3A5*1 allele [44]. With regard to tacrolimus, exposure of the renal epithelium to 
the drug in individuals carrying the CYP3A5*1 alleles was 53% of that of carriers of the CYP3A5*3 
alleles, suggesting that CYP3A5 genotype determines intrarenal accumulation of tacrolimus and its 
primary metabolites [60]. In addition, ifosfamide N-dechloroethylation was not detected using 
human kidney microsomes from CYP3A5*3/*3 donors. In contrast, microsomes from CYP3A5*1/*1 
individuals catalyzed this pathway. Thus, a higher rate of renal metabolism of ifosfamide to the 
nephrotoxic metabolite, chloroacetaldehyde, is associated with the CYP3A5*1 genotype [48]. 
CYP4A11 and CYP4F2 
CYP4A11, first cloned from a human kidney cDNA library in 1993, catalyzes formation of 20-HETE 
[61], which plays a pivotal role in the regulation of renal vascular tone and the long term control of 
arterial pressure. Within the liver both CYP4A11 and CYP4F2 are responsible for 20-HETE formation. 
CYP4F2 appears more physiologically relevant as the Km (24 μm) for AA was nearly 10-fold lower 
than that of CYP4A11 (Km 228 μm) [49] and an antibody to CYP4F2, in contrast to a CYP4A11 
antibody, markedly inhibited 20-HETE formation [49]. In the same study, CYP4A11 and CYP4F2 
expression was reported in human kidney cortex, consistent with a role for 20-HETE in controlling 
constriction of renal blood vessels [49]. Subsequent studies confirmed expression of CYP4A11 and 
CYP4F2 in the S2 and S3 segments of proximal tubules in both the cortex and outer medulla of 
human kidney. Neither P450 was found in glomeruli, loops of Henle or the collecting tubules [30]. 
Identification of 20-HETE as the major AA metabolite formed by human kidney cortical microsomes 
highlights the difference between AA metabolism in human liver and kidney and reflects the 
differing complements of P450s in these organs [30]. 
Recently the metabolism of the endocannabinoid anandamide was investigated using human kidney 
microsomes and recombinant CYP4F2 and CYP4A11 as the enzyme sources. CYP4F2 was found to 
play a major role in the metabolism of anandamide to 20-HETE-ethanolamide. In contrast, CYP4A11 
exhibited negligible activity. Anandamide exhibited a lower apparent Km (i.e. higher affinity) for 
CYP4F2 (0.7 μm) than did AA. Although the significance of this route of metabolism of anandamide is 
unknown it raises the question of a potential intrarenal interaction between anandamide and AA 
[50]. In addition, the ‘orphan’ P450 enzyme CYP4X1, which is expressed in human kidney, 
metabolizes anandamide to the monooxygenated metabolite 14,15-EET-ethanolamide. CYP4X1 also 
metabolizes AA to 14,15- and 8,9-EET to a minor extent, but the physiological significance of 
metabolism by CYP4X1 remains to be established [62]. 
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In addition to the metabolism of AA, purified human liver CYP4F2 catalyzes the metabolism of 
leukotriene B4 (LTB4) to the less biologically active metabolite 20-hydroxy LTB4. This metabolite was 
not formed by either CYP2A6, CYP2C9 or CYP4A11. Inhibition (∼92%) by an anti-CYP4F2 antibody 
further suggested that CYP4F2 is the predominant P450 that terminates biological activity of LTB4 
[51]. 
CYP4F8 
CYP4F8, which was cloned originally from human seminal vesicular mRNA, catalyzes the formation of 
18-HETE, 19-hydroxy-PGH2, and 18- and 19-hydroxy-PGH1 [52]. In contrast, PGD2, PGE1, PGE2, 
PGF2α and LTB4 were poor substrates [52]. The presence of CYP4F8 mRNA and expression of CYP4F8 
protein has been demonstrated in proximal renal tubules of human kidney [63]. To date there is no 
information regarding xenobiotic substrates of CYP4F8. 
CYP4F11 
A cDNA encoding CYP4F11 was first isolated from a human hippocampus library. Subsequent 
Northern blot analysis identified high levels of CYP4F11 mRNA transcripts in human liver and kidney 
[64]. Studies using recombinant CYP4F11 protein identified a range of endogenous and xenobiotic 
substrates. These include LTB4, AA, lipoxin A4 and 8-HETE. In contrast, lipoxin B4, 5-HETE, PGA1 and 
PGE1 were not metabolized by ω-hydroxylation [53]. Of the xenobiotic substrates studied CYP4F11 
catalyzed the dealkylation of benzphetamine, erythromycin, ethylmorphine, imipramine, 
theophylline and verapamil, and to a lesser extent, amitriptyline, chlorpromazine and pirenzepine, 
but not fluoxetine N-demethylation [53]. These xenobiotics are also metabolized by a number of 
hepatic P450s (e.g. CYP 1A2, 2D6, 3A4). Clearly CYP4F11 has broad substrate selectivity and the 
potential physiological implications in terms of drug–eicosanoid interactions are yet to be 
investigated. 
CYP4F12 
Expression of CYP4F12 was detected in human kidney using RT-PCR and activity of the recombinant 
protein was investigated using AA, PGs and LTB4 as substrates. CYP4F12 metabolized AA to one 
major metabolite, 18-HETE. In contrast, PGE2, PGF2α and LTB4 were poor substrates for ω-
hydroxylation [54]. Immunohistochemical analyses established that the vast majority of tissues did 
not contain CYP4F12. However, it was present in the human gut and the renal collecting tubules, but 
not proximal tubuli or renal cortex [65]. Catalytic studies identified lack of activity towards a number 
of long chain unsaturated fatty acids and prostaglandins (e.g. PGD2, and PGI2) [65]. Interestingly, 
however, recombinant CYP4F12 has been shown to exhibit activity towards the potent non-sedating 
H1-receptor antagonist ebastine [66]. 
Perspective 
Despite the wealth of literature on the P450 gene superfamily our knowledge of human renal P450s 
and their role in both xenobiotic and endobiotic metabolism is limited compared with hepatic 
metabolism. This is particularly relevant considering the biological activity of the ω- hydroxylated 
metabolite 20-HETE, which is a potent vasoconstrictor of renal vasculature and serves as a major 
regulator of sodium reabsorption in the proximal tubule and thick ascending limb of the loop of 
Henle [42]. Moreover animal models of hypertension have identified a role for 20-HETE in the 
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control of systemic blood pressure [42]. It has been stated that ‘members of the CYP2C and CYP4A 
gene subfamilies are the predominant and functionally relevant kidney AA epoxygenases and ω-
hydroxylases, respectively’ [67]. However, the weight of evidence from studies that have 
investigated AA metabolism using human kidney and liver tissue indicates that the CYP2C enzymes 
involved predominantly in the formation of EETs are hepatic (Figure 1, Table 2). Too often, the 
presence of P450s in human kidney has been inferred from animal data. Indeed, reviews and other 
papers that cite P450 expression as occurring in human kidney often do so without reference to the 
primary data sources. This then raises the question that if EETs are predominantly formed in the liver 
in humans, then any renal action must arise after delivery to and release from storage sites within 
the kidney. 
It appears that CYP4A11 and CYP4F2 are the principal renal enzymes involved in 20-HETE formation 
in humans (Figure 1, Table 3). However, to date no xenobiotic substrates have been identified for 
CYP4A11, CYP4F2 and CYP4F8 and hence renal drug–endobiotic interactions are unlikely. Similarly 
although xenobiotic substrates have been identified for CYP 2B6, 3A5, 4F11 and 4F12 there are no 
reports to our knowledge of renal drug–endobiotic interactions. 
At present, our knowledge of the human P450s involved in the renal metabolism of both 
endogenous and exogenous chemicals is incomplete. Thus, we are yet to fully understand the factors 
controlling renal metabolism via P450 and ultimately the physiological/pathophysiological 
significance of perturbation of renal P450 mediated metabolism. 
Renal UDP-glucuronosyltransferases 
Glucuronidation represents a major route of metabolism of both xenobiotics (Table 4) and 
endobiotics. The glucuronidation reaction involves UDP-glucuronosyltransferase (UGT) catalyzed 
conjugation of an endogenous/xenobiotic substrate with glucuronic acid, which is derived from the 
co-factor UDP-glucuronic acid (UDPGA). Given their polar nature, glucuronides are excreted in urine 
and bile. Like the P450s, UGT comprises an enzyme superfamily. UGTs have been classified in three 
families (1, 2 and 3) and four subfamilies (1A, 2A, 2B, 3A) based on amino acid sequence identity. 
Eighteen catalytically active human UGTs that utilize UDPGA as cofactor have been identified, nine 
each from the UGT1 (1A1, 1A3, 1A4, 1A5, 1A6, 1A7, 1A8, 1A9 and 1A10) and UGT2 (2A1, 2A3, 2B4, 
2B7, 2B10, 2B11, 2B15, 2B17 and 2B28) families [68, 69]. Individual UGTs exhibit distinct, but 
overlapping, substrate selectivity, and differ in terms of regulation of expression and tissue 
distribution [70]. Activity of the individual UGT enzymes is altered by factors that include age, diet, 
disease states, induction/ inhibition by xenobiotics, ethnicity, genetic polymorphism and hormonal 
factors [70, 71]. 
Using immunohistochemistry, expression of UGT1A and UGT2B7 proteins have been reported in the 
proximal convoluted tubule, loops of Henle, macula densa, epithelial cells of the distal convoluted 
tubule and medullary collecting ducts of the human nephron [72]. In contrast, no immunoreactivity 
was demonstrated in either the Bowman's capsule, the glomerulus or in veins, arteries and arterioles 
in both the cortex and medulla. Expression in the macula densa is consistent with the hypothesis 
that formation of glucuronide conjugates may modulate the biological activity of endogenous 
molecules that regulate renal haemodynamics [73]. Using RT-PCR, a subsequent study reported 
expression of UGT 1A5, 1A6, 1A7, 1A9, 2B4, 2B7 and 2B17 in human kidney. The most abundantly 
expressed UGT enzyme was UGT1A9 followed by UGT2B7 (∼80% of that of UGT1A9) [74]. 
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Importantly UGT1A9 and UGT2B7 catalyze the glucuronidation of numerous drugs (Table 4) [2, 71]. 
Taking into account the sensitivity and precision of quantitative RT-PCR, the study by Ohno & 
Nakajin indicates that UGT 1A1, 1A3, 1A4, 1A8, 1A10, 2B10, 2B11 and 2B15 are not expressed in 
human kidney [74]. 
Xenobiotic substrates of human renal UGTs 
Human kidney catalyzes formation of the glucuronide conjugates of almokalant, carbamazepine, 
codeine, edaravone, emodin, furosemide, gemfibrozil, morphine, 4-methylumbelliferone, 
mycophenolic acid, naloxone, 1-naphthol, octyl gallate, paracetamol, retigabine, valproic acid and 
the non-steroidal anti-inflammatory drugs (NSAIDs) flufenamic acid, flurbiprofen, ibuprofen, 
ketoprofen, mefenamic acid, S-naproxen and phenylbutazone. 
Studies using human kidney microsomes and recombinant UGTs have identified that almokalant 
glucuronidation is catalyzed by UGT1A9 and UGT2B7, but not by UGT 1A1, 1A3, 1A4, and 1A6 [75]. 
Similarly, UGT2B7 is involved in the N-glucuronidation of carbamazepine whereas UGT 1A1, 1A3, 
1A4, 1A6, 1A9 and 2B4 are not [76]. Edaravone, a free radical scavenger is eliminated by 
glucuronidation (∼70%) in humans [77]. A recent study has reported that the intrinsic clearance 
(CLint) of edaravone via glucuronidation was 5.4-fold higher in human kidney microsomes than 
human liver microsomes, suggesting a significant role for the kidney in the metabolism of 
edaravone. Of 12 recombinant UGTs screened, UGT 1A1, 1A6, 1A7, 1A9, 2B7 and 2B17 formed 
edaravone glucuronide and further kinetic studies established UGT1A9 as the predominant enzyme 
catalyzing edaravone glucuronidation [78]. As noted previously, UGT1A9 is expressed in human 
kidney, and during post-marketing surveillance edaravone has been implicated in causing significant 
renal dysfunction in 8.2% of patients [79]. 
Glucuronidation of codeine and naloxone has been demonstrated using human kidney and human 
liver microsomes [80, 81]. Of 13 recombinant UGT enzymes screened only UGT2B4 and UGT2B7, 
which are both expressed in kidney, catalyzed codeine glucuronidation [82]. The analgesic effect of 
codeine arises from CYP2D6 catalyzed O-demethylation to form morphine [83] and human kidney 
microsomes metabolizes morphine to both its 3- and 6-glucuronides (M3G and M6G) [81, 84]. 
Studies with a panel of recombinant UGTs have provided evidence that metabolism of morphine to 
M3G and M6G is catalyzed predominantly by UGT2B7 [85-88], with lesser contributions from UGT 
1A1, 1A3, 1A6, 1A8 and 1A9 [87, 88]. UGT 1A1, 1A3 and 1A8 are not expressed in kidney [73]. 
Furosemide is a potent diuretic and human kidney cortical and medullary microsomes both 
efficiently glucuronidate furosemide [89]. The mean CLint was ∼1.5-fold higher for cortex compared 
with medulla, 1.3 μl min−1 mg−1 and 0.88 μl min−1 mg−1, respectively. Formation of furosemide 
glucuronide was catalyzed by UGT 1A1, 1A3, 1A6, 1A7, 1A9, 1A10 and 2B7 only. Comparison of the 
kinetic parameters for furosemide glucuronidation by UGT1A9 and UGT2B7 and the use of inhibitors 
of UGT1A9 (phenylbutazone and sulfinpyrazone) and UGT2B7 (fluconazole) indicated a predominant 
role of UGT1A9 in furosemide glucuronidation [89]. These data suggest that the kidney is the main 
organ responsible for furosemide glucuronidation in vivo. 
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Hydrolysis of mycophenolate mofetil yields the active metabolite, mycophenolic acid (MPA), which is 
primarily metabolized to MPA-phenyl-glucuronide, the major metabolite, and MPA-acyl-glucuronide. 
Significant formation of MPA-phenyl-glucuronide by human kidney microsomes has been reported 
[5, 90]. In a study using human kidney and human liver microsomes CLint values for MPA-phenyl-
glucuronide and MPA-acyl-glucuronide formation were similar; 22.6 and 0.12 μl mg−1 min−1 and 
28.7 and 0.38 μl mg−1 min−1, for kidney and liver, respectively [91]. It has been demonstrated that 
UGT 1A7, 1A8, 1A9 and 1A10 all catalyze the formation of MPA-phenyl-glucuronide, with the 
greatest activity observed with UGT1A9. Minimal activity was observed with UGT 1A1, 1A6, 2B7 and 
2B4 while no activity was evident using UGT 1A3 and 1A4. In contrast, UGT2B7 is the major enzyme 
involved in MPA-acyl-glucuronide formation [91]. 
Paracetamol glucuronidation, which is catalyzed by UGT 1A1, 1A6, 1A9 and 2B15 [92, 93], occurs at a 
lower rate in human kidney in comparison with human liver microsomes [94]. UGT1A6 has 
subsequently been shown to be the major enzyme involved in paracetamol glucuronidation [95]. The 
lower activity in human kidney microsomes is consistent with the lower expression of UGT1A6 in 
human kidney in comparison with UGT1A9 [74]. 
As discussed previously propofol glucuronidation by human kidney microsomes is 3–4 times greater 
than that of human liver microsomes [6]. Since UGT1A9 is the major enzyme responsible for 
propofol glucuronidation [81, 96, 97], the high activity of human kidney microsomes reflects the high 
relative abundance of UGT1A9. Similarly UGT1A9, but not any of the other known members of the 
UGT1A and UGT2B families, is responsible for the C-glucuronidation of phenylbutazone [98]. The 
same study also reported that phenylbutazone C-glucuronidation activity by human kidney 
microsomes was 2.9-fold higher than that of human liver microsomes, again reflecting the high 
relative expression of UGT1A9 in human kidney. The antiepileptic drug retigabine undergoes N-
glucuronidation forming N2- and N4-glucuronides. Using recombinant UGT1A1, 1A4, 1A6, 1A9, 2B7 
and 2B15, Borlak et al. demonstrated that UGT1A1 (not expressed in kidney) forms the N4-
glucuronide while UGT1A4 (not expressed in kidney) and UGT1A9 (expressed in kidney) formed both 
the N2- and N4-glucuronides. Activity was not observed with UGT 1A6, 2B7, and 2B15. Not 
unexpectedly, human kidney microsomes metabolized retigabine to the N2- and N4-glucuronides 
again, reflecting the presence of UGT1A9 in human kidney [99]. 
S-Naproxen acyl glucuronide formation by human kidney cortical microsomes exhibits high and low 
affinity components. Mean CLint values (calculated as Vmax/Km), for the high- and low-affinity 
components of S-naproxen acyl glucuronidation by human kidney cortical microsomes were 
5.1 μl min−1 mg−1 and 0.73 μl min−1 mg−1, respectively [72]. The high affinity component of S-
naproxen acyl glucuronidation was inhibited by the UGT2B7 selective inhibitor fluconazole [100]. 
The similarity in Km values for S-naproxen glucuronidation by human kidney cortical microsomes 
and recombinant UGT2B7 suggests the common involvement of UGT2B7 as the high affinity enzyme 
in renal tissue [72, 101]. Ketoprofen, another propionic acid NSAID, is glucuronidated by UGT2B7 
[102] and human kidney microsomes. Indeed, the CLint for glucuronidation by human kidney 
microsomes was 2.5-fold higher than that for human liver microsomes [81]. 
The kinetics of glucuronidation of the NSAIDs flufenamic, mefenamic and niflumic acid using human 
kidney cortical microsomes, UGT1A9 and UGT2B7 as the enzyme sources have been reported [103]. 
Notably, the renal CLint of mefenamic acid (17 μl min−1 mg−1) was 15-fold higher than that of 
11 
 
niflumic acid (CLint 1.1 μl min−1 mg−1). UGT1A1 has been identified as the main hepatic enzyme 
involved in niflumic acid glucuronidation and the apparent lower CLint for niflumic acid in renal 
tissue reflects the lesser contribution from UGT1A9 and UGT2B7 [103, 104]. 
Given the predominant role of renal UGT2B7 and UGT1A9 in the glucuronidation of carboxylic acid 
containing drugs, human kidney microsomes have additionally been shown to glucuronidate 
gemfibrozil and valproic acid [81, 105], both known UGT2B7 and UGT1A9 substrates [102, 106], and 
the non-selective UGT substrate 4-methylumbelliferone (4-MU) [4]. The intrinsic clearance for 4-MU 
glucuronidation by human kidney cortical microsomes (429 μl min−1 mg−1) was comparable with 
that reported previously for human liver microsomes 414 μl min−1 mg−1 [107] and again is 
consistent with a major role of UGT1A9 in 4-MU glucuronidation [4, 108]. 
Importantly, Tsoutsikos et al. reported that unsaturated long chain fatty acids (C16:1-C20:5) were 
potent inhibitors of 4-MU glucuronidation by HKCM, UGT1A9 and UGT2B7 [4]. In particular, linoleic 
acid (C18:2) and AA were competitive inhibitors of 4-MU glucuronidation by human kidney cortical 
microsomes (Ki 6.3 and 0.15 μm, respectively), while linoleic acid was a competitive inhibitor of 
UGT1A9 (Ki 4.1 μm). These were the first data to identify fatty acids as inhibitors of renal xenobiotic 
glucuronidation [4]. 
Glucuronidation of fatty acids and eicosanoids 
In terms of endogenous substrates the kidney plays an important role in the glucuronidation of 17β-
estradiol [109-111] and aldosterone [112, 113]. However, as renal P450 and UGT enzymes are the 
focus of this review, the following sections detail the role of UGTs in the metabolism of fatty acids 
and the biosynthetic metabolites of P450 catalyzed reactions. 
Fatty acids 
In 1994 Pritchard et al. described the glucuronidation of medium chain fatty acids (C4-C10) and the 
unsaturated fatty acids linoleic acid (C18:2), α-linolenic acid (C18:3) and AA by rat UGT2B1 [114]. 
Subsequently UGT1A3 was shown to glucuronidate decanoic acid (C10:0) and lauric acid (C12:0) 
[115]. Further studies investigating fatty acid glucuronidation established that UGT2B7 
glucuronidates all C14, C16, C18 and C20 saturated and unsaturated fatty acids including AA [116]. In 
addition, UGT1A9 exhibits the same fatty acid glucuronidation profile as UGT2B7 but has ∼10-fold 
greater activity (Knights, unpublished data). Glucuronidation of AA has also been reported for UGT 
1A1, 1A3, 1A4 (minimally), 1A9, 1A10 and UGT2B7 [117]. UGT2B7 additionally glucuronidates linoleic 
acid diols [118] and the two naturally occurring metabolites of linoleic acid, 13-
hydroxyoctadecadienoic acid (13-HODE) and 13-oxooctadecadienoic acid (13-OXO) [118-121]. 
During acute renal ischaemia fatty acids accumulate intracellularly, and it is known that high 
concentrations of fatty acids and their metabolites are cytotoxic [122]. Arachidonic acid, linoleic acid 
and some linoleic acid metabolites (e.g. linoleic acid-diols) are toxic to renal proximal tubular cells, 
although the exact mechanism of toxicity is unknown [123, 124]. Given the fact that AA is a substrate 
of UGT1A9 and UGT2B7, it is apparent that glucuronidation plays a key role in both modulating 
availability of AA (and other fatty acids) for biosynthetic pathways and providing a local intra-renal 
‘detoxification’ pathway limiting the biological reactivity of AA and its bioactive metabolites. 
Prostaglandins 
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The precursor molecule for the synthesis of prostaglandins (PGs) is arachidonic acid, which is 
liberated from membrane lipids by phospholipase A2 in response to a variety of stimuli. PGs integral 
to maintaining renal function are PGI2 and PGE2. PGI2 acts as a vasodilator of cortical arterioles, 
maintains glomerular filtration, inhibits sodium reabsorption in the loop of Henle and stimulates 
renin secretion via an action in the juxtaglomerular apparatus. PGE2 is produced to a greater extent 
in the renal medulla in comparison with the cortex but its functional role is similar to PGI2 [125]. To 
date, limited studies have investigated the glucuronidation of PGs. UGT 1A1, 1A3, 1A9, 1A10 and 2B7 
form PGB1 and PGE2 glucuronides with comparable activity observed with UGT1A9 and UGT2B7 for 
PGB1. In contrast, PGE2 glucuronidation by UGT2B7 exhibits ∼12-fold greater activity in comparison 
with metabolism by UGT1A9 [117]. 
Leukotrienes 
As discussed previously LOX catalyzed metabolism of AA produces six regioisomeric HETEs along 
with the series-4 leukotrienes (e.g. LTB4). 12- and 15-HETE are potent glomerular and renal vascular 
vasoconstrictors and LOX metabolites play a key role in glomerular nephritis [126]. Similar to PGs, 
the biological activity of the HETEs and LTB4 is determined by metabolism. LTB4 is metabolized via 
both oxidative pathways and by glucuronidation. Glucuronide conjugates of LTB4, 20-COOH-LTB4 
and 10,11-dihydro-LTB4 were identified using primary cultures of human hepatocytes [127]. 
Additional conjugates of LTB4 were subsequently identified in human urine. These included the 
glucuronides of LTB4, 17-, 18-, 19-, and 20-hydroxy-LTB4, 10-hydroxy-4,6,12-octadecatrienoic acid 
and 10,11-dihydro-LTB4 [128]. Using recombinant UGT proteins it was shown that LTB4 was 
glucuronidated by UGT 1A1, 1A3, 1A8 and UGT2B7, while the biologically inactive 20-COOH-LTB4 
was glucuronidated solely by UGT1A9 [129]. 
EETs and HETEs 
In terms of the renal P450 metabolism of arachidonic acid, 20-HETE is the principal metabolite and, 
not surprisingly, 20-HETE is the focus of extensive investigation because of a link with the 
development of hypertension [26]. 20-HETE is a potent vasoconstrictor that regulates renal function 
and vascular tone, serves as a second messenger for endothelin-1 and mediates selective renal 
effects of angiotensin II. In contrast to 20-HETE, the EETs are potent vasodilators. Beyond regulation 
of the renal circulation, EETs and 20-HETE regulate sodium/potassium ATPase activity and 
sodium/potassium/chloride transport in the nephron [26]. 20-HETE glucuronide was first identified 
in human urine [130] and UGT2B7 was subsequently implicated in its formation [119]. The 
involvement of UGT2B7 was confirmed and it was further established that UGT1A1, UGT1A3, and 
UGT1A4 all catalyzed 20-HETE glucuronidation, but activity was not detected with UGT1A9 [117]. 
This clearly suggests that UGT2B7 is involved in terminating the biological activity of 20-HETE in 
human kidney. Further it was demonstrated that 5-HETE was glucuronidated by UGT 1A9, 2B4, 2B7 
and 2B10, 12-HETE by UGT 1A1, 1A3, 1A4, 1A9, 2B4, 2B7, 2B10, 2B11 and 2B15 and 15-HETE by UGT 
1A1, 1A3, 1A4, 1A8, 1A9, 2B4, 2B7, 2B10 and 2B11 [117]. Tissue specific expression of UGT enzymes 
is important in this regard. For example, in human kidney UGT 1A9 and 2B7 will play a role in the 
metabolic elimination of 5-,12- and 15-HETE (Figure 2). In contrast, in human prostate termination of 
the biological activity of 5-HETE, which promotes cell proliferation [131], will be catalyzed by 
UGT2B4 and UGT2B15 as prostate lacks UGT1A9 and UGT2B7. 
Perspective 
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UGT1A9 and UGT2B7 are the predominant UGT enzymes expressed in human kidney. In addition to 
xenobiotics (Table 4), fatty acids, prostaglandins, leukotrienes, EETs, HETEs and the 
mineralocorticoid aldosterone (along with many other hydroxy-steroids) are also metabolized by 
UGT1A9 and/or UGT2B7 (Table 5). Thus, glucuronidation can be considered an important ‘local’ 
clearance pathway as well as an essential catabolic route that modulates the duration of action of 
biologically active fatty acids and eicosanoids. Much effort has been focussed on inhibition of P450 
mediated formation of 20-HETE and EETs by imidazoles (e.g. miconazole, econazole, ketoconazole 
and clotrimazole) [132] without regard for the fact that the imidazoles are variously substrates and 
inhibitors of UGTs, in particular UGT2B7 [82, 100]. Additionally, inhibition of the formation of P450-
derived AA metabolites by selective inhibitors does not prevent release of preformed HETEs and 
EETs bound to lipids in the kidney [133]. If the ‘selective’ P450 inhibitor is also an inhibitor of 
UGT1A9 and/or UGT2B7 then it can be speculated that, following release from storage sites, the 
duration of activity of preformed 20-HETE in human kidney will persist as a result of a reduced 
clearance via glucuronidation. Consequently unravelling the complexities of AA metabolism and the 
biological activity of AA-derived metabolites in human kidney relies on recognizing not only the 
impact of inhibitors on the biosynthesis of AA metabolites by renal P450s but also on the clearance 
via glucuronidation of biologically active eicosanoids. Similarly, it follows that xenobiotic substrates 
of UGT1A9 and UGT2B7 have the potential to perturb the integrated biochemical networks that 
underpin renal function. As an example, NSAIDs inhibit aldosterone 18β-glucuronidation by human 
kidney microsomes and UGT2B7, which may subsequently lead to elevated intrarenal concentrations 
of aldosterone [73]. In turn, the retention of sodium and water would lead to volume expansion and 
a rise in blood pressure, all features of NSAID toxicity in ‘at-risk’ individuals [134]. Conversely, as 
discussed in preceding sections, many NSAIDs that are metabolized by human kidney are also 
substrates for renal UGT2B7. However, there has been little recognition of the potential role of 
NSAIDs as inhibitors of 20-HETE glucuronidation. Could this also add further to explaining the 
variable effects of NSAIDs on blood pressure? 
Conclusion 
Too often ‘metabolism’ of arachidonic acid is considered only in terms of the biosynthetic pathways 
involving P450, COX and LOX without any regard to the pivotal role of catabolism via UGTs. Animal 
models have signalled the directions to pursue in understanding the pathophysiological 
consequence of perturbation of AA metabolism, particularly in regard to hypertension. The key 
question has always been, ‘does animal data translate to humans?’ It appears that with regard to 
P450 mediated synthesis of EETs animal data have signalled the wrong organ as the presence of the 
CYP2C family of enzymes in human kidney is equivocal rather than certain, as commonly claimed in 
the literature. 
Xenobiotic inhibitors of P450s and UGTs abound. Those targeted at inhibiting the formation of EETs 
in humans should be considered inhibitors of hepatic P450s, whereas those that inhibit formation of 
HETEs, should be considered as either inhibitors of hepatic or renal P450s depending on the HETE 
formed. Similarly, with regard to UGT1A9 and UGT2B7, both enzymes are present in human liver and 
kidney and the effects of UGT inhibitors on the termination of the biological activity of AA derived 
metabolites will depend on the organ. In the kidney the consequences are somewhere between ‘the 
devil and the deep blue sea,’ that is an alteration in the balance between eicosanoids that increase 
renal blood flow and glomerular filtration and those that increase vascular resistance [135]. 
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Table 1. Representative substrates of human drug metabolising cytochrome P450 enzymes.  
Enzyme Representative Substrates 
CYP1A2* Caffeine, clozapine, dacarbazine, leflunomide, lignocaine, tacrine, 
theophylline 
CYP2A6* Nicotine 
CYP2B6 Bupropion, cyclophosphamide, efavirenz, ifosfamide, ketamine, 
propofol 
CYP2C8 Amodiaquine, chloroquine, paclitaxel, repaglinide, rosiglitazone 
CYP2C9 Losartan, NSAIDs (e.g. celecoxib, diclofenac, flurbiprofen, ibuprofen), 
oral hypoglycaemics (e.g. gliclazide, glibenclamide, glimepiride, 
glipizine, tolbutamide), phenytoin, torsemide, S-warfarin 
CYP2C19* Citalopram, escitalopram, nelfinavir, PPIs (e.g. esomeprazole, 
lansoprazole, omeprazole, pantoprazole) proguanil, voriconazole 
CYP2D6* Dextromethorphan, desipramine, fluoxetine, nortriptyline, 
perhexiline, tramadol, venlafaxine 
CYP2E1* Enflurane, halothane 
CYP3A4/5 Carbamazepine, calcium channel blockers (e.g. diltiazem, felodipine, 
nifedipine, verapamil), cyclosporin, HIV protease inhibitors (e.g. 
indinavir, lopinavir, ritonavir), midazolam, statins (e.g. atorvastatin, 
simvastatin), tacrolimus, triazolam, tyrosine kinase inhibitors (e.g. 
dasatinib, lapatinib, sorafenib, sunitinib) 
*not expressed in human kidney 
evidence for expression in human kidney equivocal 
Table 2. Formation of fatty acid metabolites by recombinant or purified P450 enzymes.  
Enzyme Metabolites Reference 
CYP1A2* 11-HODE (17%); 7-, 10-, 13-, 19-HETE 39 
CYP2C8 11-HODE (8%); 11-, 13-, 15-HETE; 
11,12-, 14,15-EET  
39 
40 
CYP2C9 11-HODE (5%); 12-, 13-HETE  
8,9-, 11,12-, 14,15-EET 
39 
40 
CYP2C19* 11-HODE (4%), 19-HETE 39 
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CYP2E1* 19-HETE 41 
CYP2J2 5,6- (21%), 8,9- (24%); 11,12- (18%), 14,15-EET (37%) 38 
CYP3A4 11-HODE (28%), 7-; 10-, 13-HETE  39 
Number in brackets indicates the percentage of total production of individual metabolites 
*not expressed in human kidney 
evidence of expression in human kidney equivocal 
Table 3. Representative endobiotic substrates of human kidney P450 enzymes. 
Enzyme Endobiotic 
substrates 
Metabolites Reference 
CYP2B6 Fatty acids, 
steroids, 
retinoids 
quinols of estrone and 17 -estradiol; 4-
hydroxy-, 4-oxo-, and 18-hydroxy-retinoic 
acid; 6 -hydroxyl metabolites of 
testosterone and 17 -methyltestosterone 
43-45 
CYP3A5 Fatty acids, 
cortisol 
19-HETE, 6 -hydroxycortisol 35, 41,  
CYP4A11 Fatty acids 19-HETE, 20-HETE 30, 49 
CYP4F2 Fatty acids,  
LTB4 
20-HETE; 20-HETE-ethanolamide; 20-
hydroxyl-LTB4 
30, 49, 51 
CYP4F8 Fatty acids, 
prostaglandins 
18-HETE; 19-hydroxy-PGH2; 18-hydroxy-
and 19-hydroxy-PGH1 
52 
CYP4F11 Fatty acids, 
leukotrienes 
8-HETE; 20-hydroxyl-LTB4 53 
CYP4F12 Fatty acids 18-HETE; 54 
 
Table 4. Representative substrates of the major drug metabolising UDP-glucuronosyltransferase 
(UGT) enzymes. 
Enzyme Representative substrates 
UGT1A1* Bilirubin, estradiol, etoposide, ethynylestradiol, SN-38 (active metabolite of 
irinotecan), raloxifene (also UGT1A9) 
UGT1A3* Telmisartan 
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UGT1A4* Lamotrigine, olanzapine, trifluoperazine 
UGT1A6 Paracetamol (also UGT 1A1, 1A9, 2B15) 
UGT1A9 Mycophenolic acid, phenylbutazone, propofol, sulfinpyrazone 
UGT2B7 Chloramphenicol, epirubicin, gemfibrozil, NSAIDs (e.g. fenoprofen, 
ketoprofen, naproxen), opioids (e.g. codeine, morphine, naloxone), valproic 
acid, zidovudine 
UGT2B15* Lorazepam, oxazepam, temazapam 
* not expressed in human kidney 
Table 5.  Glucuronidation of AA and eicosanoids by recombinant UGT1A9 and UGT2B7. 
UGT AA PGB1 PGE2 5-HETE 12-HETE 15-HETE 20-HETE LTB4 
1A9 ++ ++ + + + ++ ND ND 
2B7 + + ++ + + + ++ + 
+ = formation of glucuronide observed; ++ = enzyme with greatest activity; ND = not detected 
References: 117, 129 
Figure 1. Metabolism of arachidonic acid by hepatic and renal P450 enzymes. 
 
 
Figure 2. Metabolism of arachidonic acid and eicosanoids by renal UGTs. 
COX= cyclooxygenase; LOX = lipoxygenase 
26 
 
  
 
27 
 
